AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+36.7%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$4.37B
AUM Growth
+$4.37B
(+44%)
Cap. Flow
+$620M
Cap. Flow
% of AUM
14.19%
Top 10 Holdings %
Top 10 Hldgs %
43.92%
Holding
157
New
22
Increased
25
Reduced
24
Closed
21
Top Buys
| 1 |
Seer Inc
SEER
|
$328M |
| 2 |
SQZ
SQZ Biotechnologies Company
SQZ
|
$46.6M |
| 3 |
Zillow
Z
|
$45.4M |
| 4 |
IGMS
IGM Biosciences
IGMS
|
$45.1M |
| 5 |
Praxis Precision Medicines
PRAX
|
$41.3M |
Top Sells
| 1 |
BioNTech
BNTX
|
$59.6M |
| 2 |
Alibaba
BABA
|
$52.4M |
| 3 |
Moderna
MRNA
|
$26.1M |
| 4 |
StoneCo
STNE
|
$21.2M |
| 5 |
Scholar Rock
SRRK
|
$19.2M |
Sector Composition
| 1 | Healthcare | 82.45% |
| 2 | Consumer Discretionary | 9.72% |
| 3 | Technology | 2.14% |
| 4 | Communication Services | 1.97% |
| 5 | Real Estate | 1.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
BridgeBio Pharma
BBIO
$9.89B
| $21.3M | 0.46% | 300,000 -100,000 | -25% | -$7.11M |
|
52
Kura Oncology
KURA
$686M
| $19.6M | 0.42% | 600,000 +50,900 | +9% | +$1.66M |
|
53
Repare Therapeutics
RPTX
$71.7M
| $19.6M | 0.42% | 570,000 | – | – |
|
54
Bio-Techne
TECH
$8.5B
| $19.1M | 0.41% | 60,000 | – | – |
|
55
Iovance Biotherapeutics
IOVA
$807M
| $18.6M | 0.4% | 400,000 | – | – |
|
|
FMTX
56
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $17.5M | 0.37% | +500,000 | New | +$17.5M |
|
57
Trip.com Group
TCOM
$48.2B
| $16.9M | 0.36% | 500,000 -70,000 | -12% | -$2.36M |
|
58
Relay Therapeutics
RLAY
$619M
| $16.6M | 0.36% | 400,000 | – | – |
|
59
Zymeworks
ZYME
$1.12B
| $16.5M | 0.36% | +350,000 | New | +$16.5M |
|
|
NBTX
60
Nanobiotix
NBTX
$429M
| $16.5M | 0.35% | +1,000,000 | New | +$16.5M |
|
61
Cardiff Oncology
CRDF
$140M
| $16.2M | 0.35% | 900,000 | – | – |
|
62
Kymera Therapeutics
KYMR
$2.95B
| $15.5M | 0.33% | 250,000 | – | – |
|
63
Stoke Therapeutics
STOK
$1.08B
| $15.5M | 0.33% | 250,000 -20,750 | -8% | -$1.29M |
|
|
TCRR
64
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $15.5M | 0.33% | 500,000 | – | – |
|
65
iQIYI
IQ
$2.55B
| $14.9M | 0.32% | +850,000 | New | +$14.9M |
|
66
FibroGen
FGEN
$47.8M
| $14.8M | 0.32% | 400,000 +20,000 | +5% | +$742K |
|
67
Curis
CRIS
$20.9M
| $14.8M | 0.32% | 1,804,729 +400,000 | +28% | +$3.28M |
|
|
BLU
68
DELISTED
BELLUS Health Inc.
BLU
| $14.5M | 0.31% | 4,750,000 +4,275,000 | +900% | +$13.1M |
|
69
Krystal Biotech
KRYS
$4.27B
| $14.3M | 0.31% | 237,500 | – | – |
|
70
Y-mAbs Therapeutics
YMAB
$388M
| $14.1M | 0.3% | 285,028 | – | – |
|
71
Aurinia Pharmaceuticals
AUPH
$1.58B
| $13.8M | 0.3% | 1,000,000 | – | – |
|
72
Cartesian Therapeutics
RNAC
$261M
| $13.6M | 0.29% | 4,500,000 | – | – |
|
73
Intellia Therapeutics
NTLA
$1.22B
| $13.6M | 0.29% | 250,000 +60,000 | +32% | +$3.26M |
|
|
HARP
74
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $13.3M | 0.29% | 800,000 | – | – |
|
|
SGTX
75
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| $13.3M | 0.28% | +276,000 | New | +$13.3M |
|